1 Adams HP Jr, Bendixen BH, Kappelle LJ, et

al. Classif ication of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical

trial. TOAST. Trial of Org 10172 in Acute Stroke

Treatment[J]. Stroke, 1993, 24:35-41.

2 Amarenco P, Bogousslavsky J, Caplan LR,et al.

New approach to stroke subtyping:the A-S-C-O

(phenotypic) classification of stroke[J]. Cerebrovasc

Dis, 2009, 27:502-508.

3 Liberman AL, Prabhakaran S. Cryptogenic stroke:how

to define it? How to treat it?[J]. Curr Cardiol Rep,

2013, 15:423.

4 Ami n H, Gr e e r DM. Cr y ptogen ic st roke -the

appropriate diagnostic evaluation[J]. Curr Treat

Options Cardiovasc Med, 2014, 16:280.

5 Fr e i l i nge r TM, Sch i nd l e r A, Schmidt C, e t

al. Prevalence of nonst enosing, compl icat ed

atherosclerotic plaques in cryptogenic stroke[J]. JACC

Cardiovasc Imaging, 2012, 5:397-405.

6 Johnson BI. Paradoxical embolism[J]. J Clin Pathol,

1951, 4:316-332.

7 Lippi G, Favaloro EJ, Franchini M. Paradoxical

thrombosis par t 1:factor replacement therapy,

inherited clotting factor deficiencies and prolonged

APTT[J]. J Thromb Thrombolysis, 2012, 34:360-366.

8 Fishman AP, Pietra GG. Handling of bioactive

materials by the lung (second of two parts)[J]. N Engl

J Med, 1974, 291:953-959.

9 Meacham RR 3rd, Headley AS, Bronze MS, et al.

Impending paradoxical embolism[J]. Arch Intern Med,

1998, 158:438-448.

10 Lechat P, Mas JL, Lascault G, et al. Prevalence of

patent foramen ovale in patients with stroke[J]. N Engl

J Med, 1988, 318:1148-1152.

11 Webster MW, Chancellor AM, Smith HJ, et al. Patent

foramen ovale in young stroke patients[J]. Lancet,

1988, 332:11-12.

12 Ning M, Lo EH, Ning PC, et al. The brain's heart -

therapeutic opportunities for patent foramen ovale

(PFO) and neurovascular disease[J]. Pharmacol Ther,

2013, 139:111-123.

13 Mattle HP, Meier B, Nedeltchev K. Prevention of

stroke in patients with patent foramen ovale[J]. Int J

Stroke, 2010, 5:92-102.

14 Di Tullio MR, Jin Z, Russo C, et al. Patent foramen

ovale, subclinical cerebrovascular disease, and

ischemic stroke in a population-based cohort[J]. J Am

Coll Cardiol, 2013, 62:35-41.

15 Salem DN, Thale r DE. Pat ent for amen ovale

science:keeping the horse in front of the cart[J]. J Am

Coll Cardiol, 2013, 62:42-43.

16 Kim SJ, Shin HY, Ha YS, et al. Paradoxical embolism

as a cause of silent brain infarctions in healthy subjects:the ICONS study (Identification of the Cause

of Silent Cerebral Infarction in Healthy Subjects)[J].

Eur J Neurol, 2013, 20:353-360.

17 Ueno Y, Shimada Y, Tanaka R, et al. Patent foramen

ovale with atrial septal aneurysm may contribute to

white matter lesions in stroke patients[J]. Cerebrovasc

Dis, 2010, 30:15-22.

18 Purandare N, Oude Voshaar RC, McCollum C, et al.

Paradoxical embolisation and cerebral white matter

lesions in dementia[J]. Br J Radiol, 2008, 81:30-34.

19 Kent DM, Ruthazer R, Weimar C, et al. An index to

identify stroke-related vs incidental patent foramen

ovale in cryptogenic stroke[J]. Neurology, 2013,

81:619-625.

20 Cramer SC, Rordorf G, Maki JH, et al. Increased

pelvic vein thrombi in cryptogenic stroke:results of

the Paradoxical Emboli from Large Veins in Ischemic

Stroke (PELVIS) study[J]. Stroke, 2004, 35:46-50.

21 Lethen H, Flachskampf FA, Schneider R, et al.

Frequency of deep vein thrombosis in patients with

patent foramen ovale and ischemic stroke or transient

ischemic attack[J]. Am J Cardiol, 1997, 80:1066-1069.

22 Sandler DA, Martin JF. Autopsy proven pulmonary

embolism in hospital patients:are we detecting enough

deep vein thrombosis?[J]. J R Soc Med, 1989, 82:203-

205.

23 Palareti G, Schellong S. Isolated distal deep vein

thrombosis:what we know and what we are doing[J]. J

Thromb Haemost, 2012, 10:11-19.

24 Lehmeyer S, Lindhoff-Last E. New aspects of

paradoxical embolism[J]. Vasa, 2011, 40:31-40.

25 Spie s C, Wong M. Pat ent for amen ovale and

cryptogenic stroke:a complex neuro-cardio-vascular

problem[J]. Expert Rev Cardiovasc Ther, 2009,

7:1455-1467.

36 Rodr ig ues AC, Pica rd MH, Ca rbone A, et al.

Impor tance of adequately performed Valsalva

maneuver to detect patent foramen ovale during

transesophageal echocardiography[J]. J Am Soc

Echocardiogr, 2013, 26:1337-1343.

27 La ng hol z D, Lou ie EK, Kon s t a dt SN, e t a l .

Transesophageal echocardiographic demonstration of

distinct mechanisms for right to left shunting across

a patent foramen ovale in the absence of pulmonary

hypertension[J]. J Am Coll Cardiol, 1991, 18:1112-

1117.

28 Yang Y, Guo ZN, Wu J, et al. Prevalence and extent of

right-to-left shunt in migraine:a survey of 217 Chinese

patients[J]. Eur J Neurol, 2012, 19:1367-1372.

29 Kitsios GD, Lasker A, Singh J, et al. Recurrent stroke

on imaging and presumed paradoxical embolism:a cross-sectional analysis[J]. Neurology, 2012, 78:993-

997.

30 Kim BJ, Sohn H, Sun BJ, et al. Imaging characteristics

of ischemic strokes related to patent foramen ovale[J].

Stroke, 2013, 44:3350-3356.

31 Thaler DE, Ruthazer R, Di Angelantonio E, et al.

Neuroimaging findings in cryptogenic stroke patients

with and without patent foramen ovale[J]. Stroke,

2013, 44:675-680.

32 Liu JR, Plötz BM, Rohr A, et al. Association of

right-to-left shunt with frontal white matter lesions

in T2-weighted MR imaging of stroke patients[J].

Neuroradiology, 2009, 51:299-304.

33 Furlan AJ, Reisman M, Massaro J, et al. Closure or

medical therapy for cryptogenic stroke with patent

foramen ovale[J]. N Engl J Med, 2012, 366:991-999.

34 Meier B, Kalesan B, Mattle HP, et al. Percutaneous

closure of patent foramen ovale in cryptogenic

embolism[J]. N Engl J Med, 2013, 368:1083-1091.

35 Carroll JD, Saver JL, Thaler DE, et al. Closure of

patent foramen ovale versus medical therapy after

cryptogenic stroke[J]. N Engl J Med, 2013, 368:1092-

1100.

36 Calvet D, Mas JL. Closure of patent foramen ovale in

cryptogenic stroke:a never ending story[J]. Curr Opin

Neurol, 2014, 27:13-19.

37 Nendaz MR, Sarasin FP, Junod AF, et al. Preventing

stroke recurrence in patients with patent foramen

ovale:antithrombotic therapy, foramen closure,

or therapeutic abstention? A decision analytic

perspective[J]. Am Heart J, 1998, 135:532-541.

38 Moh r J P, Thompson JL, La z a r RM, e t a l. A

comparison of warfarin and aspirin for the prevention

of recurrent ischemic stroke[J]. N Engl J Med, 2001,

345:1444-1451.

39 Fischer D, Gardiwal A, Haentjes J, et al. Sustained risk

of recurrent thromboembolic events in patients with

patent foramen ovale and paradoxical embolism:longterm

follow-up over more than 15 years[J]. Clin Res

Cardiol, 2012, 101:297-303.

40 Thaler DE, Kent DM. Rethinking trial strategies for

stroke and patent foramen ovale[J]. Curr Opin Neurol,

2010, 23:73-78.

41 Windecker S, Meier B. Is closure recommended for

patent foramen ovale and cryptogenic stroke? Patent

foramen ovale and cryptogenic stroke:to close or not

to close? Closure:what else![J]. Circulation, 2008,

118:1989-1998.